피네레논(BAY94-8862)
|
|
피네레논(BAY94-8862) 속성
- 끓는 점
- 554.7±50.0 °C(Predicted)
- 밀도
- 1.29±0.1 g/cm3(Predicted)
- 저장 조건
- -20°C
- 용해도
- DMF: 10 mg/ml DMSO: 3 mg/ml Ethanol: insol PBS (pH 7.2): insol
- 산도 계수 (pKa)
- 14.76±0.40(Predicted)
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 최대 파장(λmax)
- 255 nm
- InChI
- InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
- InChIKey
- BTBHLEZXCOBLCY-QGZVFWFLSA-N
- SMILES
- N1C2=C(C(OCC)=NC=C2C)[C@H](C2=CC=C(C#N)C=C2OC)C(C(N)=O)=C1C
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
피네레논(BAY94-8862) C화학적 특성, 용도, 생산
개요
Finerenone is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022.상표명
Finerenone is sold under the brand name Kerendia and Firialta.Mode of action
Finerenone is a Nonsteroidal Mineralocorticoid-Receptor Antagonist. The mechanism of action of finerenone is as a Mineralocorticoid Receptor Antagonist. Finerenone inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated, possibly reducing inflammation and fibrosis in the heart and kidney.참고 문헌
Kolkhof, P., Hartmann, E., Freyberger, A., et al.Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).DOI: 10.1159/000516213
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
피네레논(BAY94-8862) 준비 용품 및 원자재
원자재
준비 용품
피네레논(BAY94-8862) 공급 업체
글로벌( 212)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| Beijing Mesochem Technology Co.,Ltd | +8613651027935 |
rachel@mesochem.com | China | 191 | 58 |
| Zison Pharmaceutical (Shandong) Co., Ltd. | +86-0086-531-88259693 +86-18660188356 |
maguanglei@zisonpharm.com | China | 57 | 58 |
| Chengdu Aupone Pharmaceutical Co.Ltd. | +86-28-+86-28-87843998-6060-6060 +8618631098571 |
lijiaqi@aupone.com | China | 43 | 58 |
| Auschemicals Pty Ltd | +61406202619 |
info@auschemicals.com | Australia | 431 | 58 |
| Tianjin Kilo Pharmaceutical Sci-Tech Co., Ltd | +86-02223869539 +86-15560057295 |
trade.kilopharma@foxmail.com | China | 27 | 58 |
| Wuhan Marco Pharmaceutical Technology Co., Ltd. | +86-86-18572802410 +8618572802410 |
sales@marcopht.com | China | 55 | 58 |
| Beijing Hope Pharmaceutical Co., Ltd. | +86-010-67886402 +8613611125266 |
market@hopelife.cn | China | 71 | 58 |
| shandong perfect biotechnology co.ltd | +86-53169958659; +8618596095638 |
sales@sdperfect.com | China | 294 | 58 |
| Hangzhou ICH Biofarm Co., Ltd | +86-0571-28186870; +undefined8613073685410 |
sales@ichemie.com | China | 985 | 58 |
| Zibo Wei Bin Import & Export Trade Co. Ltd. | +86-0533-2091136 +8613864437655 |
ziboweibinmaoyi@163.com | China | 100 | 58 |